the University of Pennsylvania Perelman School of Medicine
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.
A personalized vaccine for melanoma cut the risk of cancer returning after five years
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The research, presented Monday at the American Society of Clinical Oncology’s annual meeting, found that a personalized mRNA vaccine halved the risk of melanoma returning after five years. The results were also published in the Journal of Clinical Oncology.
Weight-loss drugs may cut breast cancer risk by up to 30%, study finds
Women on weight-loss medication may have a lower risk of developing breast cancer, according to a new study. Women who take GLP-1 medications, such as Ozempic or Mounjaro, are less likely to develop breast cancer, a new study has found. The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, come from an analysis of more than 110,000 women aged between 45 and 80.